Ftse Mib
33.947,50
0,20%
DAX
18.957,50
-0,16%
S&P 500
5.732,93
0,00%
NASDAQ
18.074,52
0,00%
Bitcoin
63.682,86
-0,91%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ MannKind Corporation (MNKD) MannKind Corporation (MNKD) Notizie

MNKD

MannKind (MNKD)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MNKD
DataOraFonteTitoloSimboloCompagnia
18/09/202412:15GlobeNewswire Inc.MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseNASDAQ:MNKDMannKind Corporation
10/09/202422:30GlobeNewswire Inc.MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:MNKDMannKind Corporation
05/09/202403:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
03/09/202422:25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MNKDMannKind Corporation
27/08/202422:30GlobeNewswire Inc.MannKind to Present at Upcoming ConferencesNASDAQ:MNKDMannKind Corporation
14/08/202414:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNKDMannKind Corporation
14/08/202414:00GlobeNewswire Inc.Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the BoardNASDAQ:MNKDMannKind Corporation
07/08/202414:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MNKDMannKind Corporation
07/08/202414:00GlobeNewswire Inc.MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development UpdateNASDAQ:MNKDMannKind Corporation
07/08/202411:49IH Market NewsUS Index Futures Rise Amid Earnings Season Optimism, Oil Prices ReboundNASDAQ:MNKDMannKind Corporation
31/07/202412:30GlobeNewswire Inc.MannKind Launches Educational Website to Raise Awareness of NTM Lung DiseaseNASDAQ:MNKDMannKind Corporation
30/07/202422:30GlobeNewswire Inc.MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024NASDAQ:MNKDMannKind Corporation
22/06/202414:00GlobeNewswire Inc.INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific SessionsNASDAQ:MNKDMannKind Corporation
05/06/202412:45GlobeNewswire Inc.Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific SessionsNASDAQ:MNKDMannKind Corporation
29/05/202414:45GlobeNewswire Inc.MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With PulmatrixNASDAQ:MNKDMannKind Corporation
08/05/202422:18GlobeNewswire Inc.MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development UpdateNASDAQ:MNKDMannKind Corporation
06/05/202412:05GlobeNewswire Inc.MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseNASDAQ:MNKDMannKind Corporation
01/05/202422:00GlobeNewswire Inc.MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024NASDAQ:MNKDMannKind Corporation
30/04/202412:05GlobeNewswire Inc.MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic DiseasesNASDAQ:MNKDMannKind Corporation
29/04/202412:05GlobeNewswire Inc.MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung DiseaseNASDAQ:MNKDMannKind Corporation
03/04/202412:00GlobeNewswire Inc.MannKind Repays Certain Debt ObligationsNASDAQ:MNKDMannKind Corporation
26/03/202421:05GlobeNewswire Inc.MannKind Announces CFO TransitionNASDAQ:MNKDMannKind Corporation
11/03/202411:05GlobeNewswire Inc.INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin PumpsNASDAQ:MNKDMannKind Corporation
05/03/202412:05GlobeNewswire Inc.MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8NASDAQ:MNKDMannKind Corporation
04/03/202419:01GlobeNewswire Inc.MannKind Corporation Announces Participation at Upcoming ConferencesNASDAQ:MNKDMannKind Corporation
27/02/202422:00GlobeNewswire Inc.MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development UpdateNASDAQ:MNKDMannKind Corporation
20/02/202412:00GlobeNewswire Inc.MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024NASDAQ:MNKDMannKind Corporation
15/02/202412:05GlobeNewswire Inc.MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®NASDAQ:MNKDMannKind Corporation
02/01/202412:05GlobeNewswire Inc.MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 MillionNASDAQ:MNKDMannKind Corporation
28/12/202312:00GlobeNewswire Inc.MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MNKDMannKind Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MNKD

La tua Cronologia

TG
D1NC
DNB Bank ASA
EU
CNPAR
CNP Assurances SA 2.75% ...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network